Saved in:
| Main Authors: | Abel Tesfai, Natalia Norori, Thomas A. Harding, Yui Hang Wong, Matthew David Hobbs |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | https://bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bco2.321 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review
by: Abel Tesfai, et al.
Published: (2024)
by: Abel Tesfai, et al.
Published: (2024)
Impact of multiparametric MRI and prostate biopsies on anxiety and quality of life in men with suspected prostate cancer
by: Esther H. J. Hamoen, et al.
Published: (2025)
by: Esther H. J. Hamoen, et al.
Published: (2025)
Omission of contralateral biopsies in unilateral MRI‐suspicious prostate cancer has minimal impact on clinical risk assessment
by: Stijn M. van den Bosch, et al.
Published: (2026)
by: Stijn M. van den Bosch, et al.
Published: (2026)
Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer
by: Yuki Teramoto, et al.
Published: (2026)
by: Yuki Teramoto, et al.
Published: (2026)
Cost‐effectiveness analysis of a biopsy‐free diagnostic strategy for prostate cancer using mpMRI and PSMA‐PET/CT
by: Joshua Yi Min Tung, et al.
Published: (2026)
by: Joshua Yi Min Tung, et al.
Published: (2026)
Perioperative antibiotic prophylaxis, prostate size and transperineal prostate biopsy
by: Maxwell Louis Sandberg, et al.
Published: (2026)
by: Maxwell Louis Sandberg, et al.
Published: (2026)
The carbon footprint of transperineal prostate biopsy
by: Daniel A. Carson, et al.
Published: (2025)
by: Daniel A. Carson, et al.
Published: (2025)
AI‐enhanced micro‐ultrasound improves detection of clinically significant prostate cancer at biopsy
by: Muhammad Imran, et al.
Published: (2026)
by: Muhammad Imran, et al.
Published: (2026)
Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer
by: Agnieszka Krzyzanowska, et al.
Published: (2024)
by: Agnieszka Krzyzanowska, et al.
Published: (2024)
Perioperative alpha blockers in voiding dysfunction secondary to prostate biopsy: A meta‐analysis
by: Sean Lim, et al.
Published: (2024)
by: Sean Lim, et al.
Published: (2024)
National survey of urologists' views on prostate cancer screening in the United Kingdom
by: Nikhil Mayor, et al.
Published: (2026)
by: Nikhil Mayor, et al.
Published: (2026)
Transperineal prostate biopsy with freehand technique under local anaesthetic: A systematic review and meta‐analysis
by: Benjamin M. Mac Curtain, et al.
Published: (2025)
by: Benjamin M. Mac Curtain, et al.
Published: (2025)
Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer
by: Arjun Pon Avudaiappan, et al.
Published: (2024)
by: Arjun Pon Avudaiappan, et al.
Published: (2024)
Focal therapy in prostate cancer: Development, application and outcomes in the United Kingdom
by: Nadia Rokan, et al.
Published: (2025)
by: Nadia Rokan, et al.
Published: (2025)
Risk factors of negative prostate biopsies: A CHAID decision tree analysis
by: Pierre Allainguillaume, et al.
Published: (2026)
by: Pierre Allainguillaume, et al.
Published: (2026)
‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer
by: Ryan Sutherland, et al.
Published: (2024)
by: Ryan Sutherland, et al.
Published: (2024)
Does bladder outflow obstruction obfuscate the traditional clinical factors that are used to assess the risk of prostate cancer at rapid‐access diagnostic clinics?
by: Thomas Philip Cahill, et al.
Published: (2024)
by: Thomas Philip Cahill, et al.
Published: (2024)
Effect of prior HoLEP procedure on multiparametric MRI accuracy in detection of prostate cancer
by: Austin Drysch, et al.
Published: (2025)
by: Austin Drysch, et al.
Published: (2025)
MRI performance to identify clinically significant prostate cancer following focal cryo‐ablation
by: Herbert Lepor, et al.
Published: (2025)
by: Herbert Lepor, et al.
Published: (2025)
Real‐world clinical outcomes of oligometastatic prostate cancer using SBRT: An Australian experience
by: Samantha Shekar, et al.
Published: (2025)
by: Samantha Shekar, et al.
Published: (2025)
The impact of biopsy core length on the discrepancy in Gleason scores between biopsy and radical prostatectomy specimen
by: Cheng‐hao Guo, et al.
Published: (2025)
by: Cheng‐hao Guo, et al.
Published: (2025)
Concordance with final pathology when transitioning from standard transrectal to cognitive targeted transperineal prostate biopsy
by: Alfred Honoré, et al.
Published: (2025)
by: Alfred Honoré, et al.
Published: (2025)
Analysis of urinary volatile organic compounds for prostate cancer diagnosis: A systematic review
by: Jonathon Dawson, et al.
Published: (2024)
by: Jonathon Dawson, et al.
Published: (2024)
Oncological outcomes post focal low‐dose‐rate brachytherapy in low‐intermediate risk prostate cancer
by: Mohammadmehdi Adhami, et al.
Published: (2026)
by: Mohammadmehdi Adhami, et al.
Published: (2026)
Genomic prostate score and treatment selection in favourable intermediate‐risk prostate cancer
by: Eric Margolis, et al.
Published: (2025)
by: Eric Margolis, et al.
Published: (2025)
Comparing outcomes of Aquablation versus holmium laser enucleation of prostate in the treatment of benign prostatic hyperplasia: A network meta‐analysis
by: Ansh Bhatia, et al.
Published: (2024)
by: Ansh Bhatia, et al.
Published: (2024)
Sociodemographic landscape of suspected prostate cancer referrals and diagnoses across North East London
by: Muhammad Haider, et al.
Published: (2025)
by: Muhammad Haider, et al.
Published: (2025)
A sustainable and expedited ‘One‐Stop’ prostate cancer diagnostic pathway to reduce environmental impact and enhance accessibility
by: Lorenzo Storino Ramacciotti, et al.
Published: (2024)
by: Lorenzo Storino Ramacciotti, et al.
Published: (2024)
Emerging tools for the early detection of prostate cancer
by: Muhammad Haider, et al.
Published: (2025)
by: Muhammad Haider, et al.
Published: (2025)
Quality of English‐ and Spanish‐language online content about prostate cancer genetics: Insights into potential contributors to prostate cancer disparities
by: Sophia M. Abusamra, et al.
Published: (2025)
by: Sophia M. Abusamra, et al.
Published: (2025)
Extended versus limited pelvic lymph node dissection and long‐term outcomes in high‐risk prostate cancer before radiotherapy
by: Georgios Daouacher, et al.
Published: (2026)
by: Georgios Daouacher, et al.
Published: (2026)
Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies
by: Laurence Klotz, et al.
Published: (2024)
by: Laurence Klotz, et al.
Published: (2024)
Bibliometric analysis of focal therapy in prostate cancer research
by: Mohammed Shahait, et al.
Published: (2024)
by: Mohammed Shahait, et al.
Published: (2024)
Multivariable model integrating PHI and mpMRI for detecting csPCa in biopsy‐naïve men
by: Mario Dominguez Esteban, et al.
Published: (2025)
by: Mario Dominguez Esteban, et al.
Published: (2025)
Does total lesion prostate‐specific membrane antigen (PSMA) activity on 68Ga‐PSMA PET/CT correlate with PSA and prostatectomy histopathological/clinical outcomes in patients with localised primary prostate cancer?
by: Jeremy Cheng, et al.
Published: (2025)
by: Jeremy Cheng, et al.
Published: (2025)
Comparing GreenLight PVP and HoLEP beyond 5 years: A systematic review of long‐term functional outcomes and reoperation rates
by: Arthur Yim, et al.
Published: (2025)
by: Arthur Yim, et al.
Published: (2025)
The impact of vaporization on adenoma weight in benign prostatic hyperplasia surgery
by: André B. Silva, et al.
Published: (2026)
by: André B. Silva, et al.
Published: (2026)
Comparison of staging MRI to re‐resection for localised bladder cancer: Narrative review
by: Hugo Klempfner, et al.
Published: (2024)
by: Hugo Klempfner, et al.
Published: (2024)
Micro‐ultrasound tissue echogenicity predicts prostate cancer grade
by: Ailene E. Corona, et al.
Published: (2026)
by: Ailene E. Corona, et al.
Published: (2026)
PARP inhibitor‐based treatment in metastatic, castration‐resistant prostate cancer (mCRPC): A systematic review and meta‐analysis
by: Michela Roberto, et al.
Published: (2025)
by: Michela Roberto, et al.
Published: (2025)
Similar Items
-
Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review
by: Abel Tesfai, et al.
Published: (2024) -
Impact of multiparametric MRI and prostate biopsies on anxiety and quality of life in men with suspected prostate cancer
by: Esther H. J. Hamoen, et al.
Published: (2025) -
Omission of contralateral biopsies in unilateral MRI‐suspicious prostate cancer has minimal impact on clinical risk assessment
by: Stijn M. van den Bosch, et al.
Published: (2026) -
Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer
by: Yuki Teramoto, et al.
Published: (2026) -
Cost‐effectiveness analysis of a biopsy‐free diagnostic strategy for prostate cancer using mpMRI and PSMA‐PET/CT
by: Joshua Yi Min Tung, et al.
Published: (2026)